Show simple item record

dc.contributor.authorBisogno, G
dc.contributor.authorMinard-Colin, V
dc.contributor.authorJenney, M
dc.contributor.authorFerrari, A
dc.contributor.authorChisholm, J
dc.contributor.authorDi Carlo, D
dc.contributor.authorHjalgrim, LL
dc.contributor.authorOrbach, D
dc.contributor.authorMerks, JHM
dc.contributor.authorCasanova, M
dc.coverage.spatialSwitzerland
dc.date.accessioned2023-10-18T14:55:28Z
dc.date.available2023-10-18T14:55:28Z
dc.date.issued2023-08-07
dc.identifierARTN 4012
dc.identifiercancers15154012
dc.identifier.citationCancers, 2023, 15 (15), pp. 4012 -en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6020
dc.identifier.eissn2072-6694
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers15154012
dc.description.abstractMaintenance chemotherapy (MC) defines the administration of prolonged relatively low-intensity chemotherapy with the aim of "maintaining" tumor complete remission. This paper aims to report an update of the RMS2005 trial, which demonstrated better survival for patients with high-risk localized rhabdomyosarcoma (RMS) when MC with vinorelbine and low-dose cyclophosphamide was added to standard chemotherapy, and to discuss the published experience on MC in RMS. In the RMS2005 study, the outcome for patients receiving MC vs. those who stopped the treatment remains superior, with a 5-year disease-free survival of 78.1% vs. 70.1% (p = 0.056) and overall survival of 85.0% vs. 72.4% (p = 0.008), respectively. We found seven papers describing MC in RMS, but only one randomized trial that did not demonstrate any advantage when MC with eight courses of trofosfamide/idarubicine alternating with trofosfamide/etoposide has been employed in high-risk RMS. The use of MC showed better results in comparison to high-dose chemotherapy in non-randomized studies, including metastatic patients, and demonstrated feasibility and tolerability in relapsed RMS. Many aspects of MC in RMS need to be investigated, including the best drug combination and the optimal duration. The ongoing EpSSG trial will try to answer some of these questions.
dc.formatElectronic
dc.format.extent4012 -
dc.languageeng
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofCancers
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectlow-dose chemotherapy
dc.subjectmaintenance chemotherapy
dc.subjectmetronomic chemotherapy
dc.subjectrhabdomyosarcoma
dc.titleMaintenance Chemotherapy for Patients with Rhabdomyosarcoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-07-28
dc.date.updated2023-10-18T11:30:45Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cancers15154012en_US
rioxxterms.licenseref.startdate2023-08-07
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37568826
pubs.issue15
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People
pubs.organisational-groupICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people
pubs.organisational-groupICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.organisational-groupICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.)
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.3390/cancers15154012
pubs.volume15
dc.contributor.icrauthorChisholm, Julia
icr.provenanceDeposited by Dr Julia Chisholm on 2023-10-18. Deposit type is initial. No. of files: 1. Files: Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/